lvrachЛечащий ВрачLechaschi Vrach1560-51752687-1181lvrach-565Research ArticleСтатьиПодагра, гиперурикемия и сердечно-сосудистые заболевания. Подходы к фармакотерапииGout, hyperuricemy and cardiovascular diseases. Approaches to pharmacotherapyЦуркоВ. В.TsurkoV. V.vvtsurko@mail.ruМорозоваТ. Е.MorozovaT. E.noemail@neicon.ruФГАОУ ВО Первый МГМУ им. И. М. Сеченова МЗ РФRussian Federation201823062021085252Copyright © Цурко В.В., Морозова Т.Е., 20212021Цурко В.В., Морозова Т.Е.Tsurko V.V., Morozova T.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.lvrach.ru/jour/article/view/565

Рассмотрены подходы к ведению пациентов с подагрой или гиперурикемией, показана необходимость скрининга и коррекции пуринового, липидного и углеводного обменов, а также мероприятий, направленных на предотвращение кардиоваскулярных осложнений.

Approaches to conducting patients with gout or hyperuricemy were considered, the necessity of screening and correction of purine, lipid and hydrocarbon metabolism was indicated, as well as the measures directed to prevention of cardiovascular complications. 

Актуальная темаПодаграГиперурикемияСердечно-сосудистые заболеванияОсложненияФармакотерапияgouthyperuricemycardiovascular diseasescomplicationspharmacotherapyReferencesMaiuolo J., Oppedisano F., Gratteri S. et al. Regulation of uric acid metabolism and excretion // Int. J. Cardiol. 2016; 213: 8–14. DOI: 10.1016/j.ijcard.2015.08.109, indexed in Pubmed: 26316329.Maiuolo J., Oppedisano F., Gratteri S. et al. Regulation of uric acid metabolism and excretion // Int. J. Cardiol. 2016; 213: 8–14. DOI: 10.1016/j.ijcard.2015.08.109, indexed in Pubmed: 26316329.Gaffo A. L., Lawrence E. N., Saag K. G. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? // Arthritis Res. Therapy. 2009; 11 (Issue 4): 240–249.Gaffo A. L., Lawrence E. N., Saag K. G. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? // Arthritis Res. Therapy. 2009; 11 (Issue 4): 240–249.Kumar H. K. V. S., Marwaha V. Chronic Tophaceous Gout // Int. J. Med. Health Sci. 2012; 1 (1): 31–32.Kumar H. K. V. S., Marwaha V. Chronic Tophaceous Gout // Int. J. Med. Health Sci. 2012; 1 (1): 31–32.Насонов Е. Л., Насонова В. А. Ревматология: национальное руководство. М.: ГЕОТАР-Медиа, 2008. 720 с.Насонов Е. Л., Насонова В. А. Ревматология: национальное руководство. М.: ГЕОТАР-Медиа, 2008. 720 с.Компания «ЭГИС» собрала статистику о распространенности гиперурикемии в сочетании с артериальной гипертензией и сопутствующими заболеваниями среди российских пациентов // Поликлиника. Спецвыпуск. 2017; 4: 16.Компания «ЭГИС» собрала статистику о распространенности гиперурикемии в сочетании с артериальной гипертензией и сопутствующими заболеваниями среди российских пациентов // Поликлиника. Спецвыпуск. 2017; 4: 16.Smith E., Hoy D., Cross M. et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study // Ann. Rheum. Dis. 2014; 73 (8): 1470–1476. DOI: 10.1136/annrheumdis2013204647; indexed in Pubmed: 24590182.Smith E., Hoy D., Cross M. et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study // Ann. Rheum. Dis. 2014; 73 (8): 1470–1476. DOI: 10.1136/annrheumdis2013204647; indexed in Pubmed: 24590182.Roddy E., Choi H. K. Epidemiology of gout. Rheum. Dis. Clin. North Am. 2014; 40 (2): 155–175. DOI: 10.1016/i.rdc.2014.01.001; indexed in Pubmed: 24703341.Roddy E., Choi H. K. Epidemiology of gout. Rheum. Dis. Clin. North Am. 2014; 40 (2): 155–175. DOI: 10.1016/i.rdc.2014.01.001; indexed in Pubmed: 24703341.Conen D., Wietlisbach V., Bovet P. et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country // BMC Public Health. 2004; 4: 9. DOI: 10.1186/1471245849; indexed in Pubmed: 15043756.Conen D., Wietlisbach V., Bovet P. et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country // BMC Public Health. 2004; 4: 9. DOI: 10.1186/1471245849; indexed in Pubmed: 15043756.Qiu L., Cheng Xq., Wu J. et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces // BMC Public Health. 2013; 13: 664, DOI: 10.1186/1471245813664; indexed in Pubmed: 23866159.Qiu L., Cheng Xq., Wu J. et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces // BMC Public Health. 2013; 13: 664, DOI: 10.1186/1471245813664; indexed in Pubmed: 23866159.Liu S. C., Xia L., Zhang J. et al. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies // PLoS ONE. 2015; 10: e 0134088.Liu S. C., Xia L., Zhang J. et al. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies // PLoS ONE. 2015; 10: e 0134088.Clarson L. E., Hider S. L., Belcher J. et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink // Ann. Rheum. Dis. 2015; 74: 642–647.Clarson L. E., Hider S. L., Belcher J. et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink // Ann. Rheum. Dis. 2015; 74: 642–647.Choi H. K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease // Circulation. 2007; 116: 894–900.Choi H. K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease // Circulation. 2007; 116: 894–900.Norvik J. V., Storhaug H. M., Ytrehus K. et al. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromso Study // BMC Cardiovasc. Disord. 2016; 16: 85–98.Norvik J. V., Storhaug H. M., Ytrehus K. et al. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromso Study // BMC Cardiovasc. Disord. 2016; 16: 85–98.Perlstein T. S., Gumieniak O., Williams G. H. et al. Uric acid and the development of hypertension: the normative aging study // Hypertension. 2006; 48 (6): 1031–1036. DOI: 10.1161/01.HYP.0000248752.08807.4 c. indexed in Pubmed: 17060508.Perlstein T. S., Gumieniak O., Williams G. H. et al. Uric acid and the development of hypertension: the normative aging study // Hypertension. 2006; 48 (6): 1031–1036. DOI: 10.1161/01.HYP.0000248752.08807.4 c. indexed in Pubmed: 17060508.Syamala S., Li J., Shankar A. Association between serum uric acid and prehypertension among US adults // J. Hypertens. 2007; 25 (8): 1583–1589. DOI: 10.1097/HJH.0b013e32813aeb6c; indexed in Pubmed: 17620953.Syamala S., Li J., Shankar A. Association between serum uric acid and prehypertension among US adults // J. Hypertens. 2007; 25 (8): 1583–1589. DOI: 10.1097/HJH.0b013e32813aeb6c; indexed in Pubmed: 17620953.Hyon K., Choi E., Ford S. et al. Prevalence of the Metabolic Syndrome in Patients With Gout: The Third National Health and Nutrition Examination Survey // Arthr. Rheum. 2007; 57: 1: 109–115.Hyon K., Choi E., Ford S. et al. Prevalence of the Metabolic Syndrome in Patients With Gout: The Third National Health and Nutrition Examination Survey // Arthr. Rheum. 2007; 57: 1: 109–115.Puig J. G., Mart?nez M. A. Hyperurecemia, Gout and the Metabolic Syndrome // Curr. Opin. Rheumatol. 2008; 20: 2: 187–191.Puig J. G., Mart?nez M. A. Hyperurecemia, Gout and the Metabolic Syndrome // Curr. Opin. Rheumatol. 2008; 20: 2: 187–191.Borona E., Kiechl S., Willeit J. et al. Prevalence of insulin resistance in metabolic disorders // Diabetes. 1998; 47: 1643–1649.Borona E., Kiechl S., Willeit J. et al. Prevalence of insulin resistance in metabolic disorders // Diabetes. 1998; 47: 1643–1649.Lakka H. M., Laaksonen D. E., Lakka T. A. et al. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men // JAMA. 2002; 288: 2709–2716.Lakka H. M., Laaksonen D. E., Lakka T. A. et al. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men // JAMA. 2002; 288: 2709–2716.Dessein P., Shipton E., Stanwix A. et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study // Ann. Rheum. Dis. 2000; 59: 539–543.Dessein P., Shipton E., Stanwix A. et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study // Ann. Rheum. Dis. 2000; 59: 539–543.Rho Y. H., Choi S. J., Lee Y. H. et al. The prevalence of metabolic syndrome in patients with gout: A multicenter study // J. Korean Med. Sci. 2005; 20: 1029–1033.Rho Y. H., Choi S. J., Lee Y. H. et al. The prevalence of metabolic syndrome in patients with gout: A multicenter study // J. Korean Med. Sci. 2005; 20: 1029–1033.Edwards N. L. The role of hyperuricemia and gout in kidney and cardiovascular disease // Clev. Clin. J. Med. 2008; 75: 13–16.Edwards N. L. The role of hyperuricemia and gout in kidney and cardiovascular disease // Clev. Clin. J. Med. 2008; 75: 13–16.Johnson R. J., Kang D. H., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? // Hypertension. 2003; 41: 1183–1190.Johnson R. J., Kang D. H., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? // Hypertension. 2003; 41: 1183–1190.Ouppatham S., Bancha S., Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population // J. Postgrad. Med. 2008; 54 (4): 259–262.Ouppatham S., Bancha S., Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population // J. Postgrad. Med. 2008; 54 (4): 259–262.Mazzali M., Hughes J., Kim Y. G. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism // Hypertension. 2001; 38 (5): 1101–1106.Mazzali M., Hughes J., Kim Y. G. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism // Hypertension. 2001; 38 (5): 1101–1106.Feig D. I., Kang D., Johnson R. J. Uric acid and cardiovascular risk // N. Engl. J. Med. 2008; 359 (17): 1811–1821.Feig D. I., Kang D., Johnson R. J. Uric acid and cardiovascular risk // N. Engl. J. Med. 2008; 359 (17): 1811–1821.Sidiropoulos P. I., Karvounaris S. A., Boumpas D. T. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology and clinical implications // Arthr. Res. Ther. 2008; 10: 207–216.Sidiropoulos P. I., Karvounaris S. A., Boumpas D. T. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology and clinical implications // Arthr. Res. Ther. 2008; 10: 207–216.Воробьев П. А., Цурко В. В., Елисеева М. Е. Подагра в гериатрической практике (Методические рекомендации. Часть I) // Клин. геронтол. 2016; 3–4 (22): 3–9.Воробьев П. А., Цурко В. В., Елисеева М. Е. Подагра в гериатрической практике (Методические рекомендации. Часть I) // Клин. геронтол. 2016; 3–4 (22): 3–9.Janssens H. J., van de Lisdonk E. H., Bor H. et al. Gout, just a nasty event or a cardiovascular signal? A study from primary care // Fam. Pract. 2003; 20: 413–416.Janssens H. J., van de Lisdonk E. H., Bor H. et al. Gout, just a nasty event or a cardiovascular signal? A study from primary care // Fam. Pract. 2003; 20: 413–416.Bhansing K. J., Bon L., Janssen M. et al. Gout: a clinical syndrome illustrated and discussed // Nether. J. Med. 2010; 68 (9): 352–359.Bhansing K. J., Bon L., Janssen M. et al. Gout: a clinical syndrome illustrated and discussed // Nether. J. Med. 2010; 68 (9): 352–359.Janssens H. J., van de Lisdonk E. H., Janssen M. et al. Gout, not induced by diuretics? A case-control study from primary care // Ann. Rheum. Dis. 2006; 65 (8): 1080–1083.Janssens H. J., van de Lisdonk E. H., Janssen M. et al. Gout, not induced by diuretics? A case-control study from primary care // Ann. Rheum. Dis. 2006; 65 (8): 1080–1083.Akkineni R., Tapp S., Tosteson A. N. A. et al. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach // J. Rheumatol. 2014; 41 (4): 739–748. DOI: 10.3899/irheum.l21231; indexed in Pubmed: 24584921.Akkineni R., Tapp S., Tosteson A. N. A. et al. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach // J. Rheumatol. 2014; 41 (4): 739–748. DOI: 10.3899/irheum.l21231; indexed in Pubmed: 24584921.Widecka K., Szymanski F. М., Filipiak K. J. et al. Hyperuricemia and its treatment in patients with a high cardio-vascular risk — experts opinion // Arterial. Hypertens. 2017; 21 (1): 10–17. DOI: 10.5603/AH.2017.0002.Widecka K., Szymanski F. М., Filipiak K. J. et al. Hyperuricemia and its treatment in patients with a high cardio-vascular risk — experts opinion // Arterial. Hypertens. 2017; 21 (1): 10–17. DOI: 10.5603/AH.2017.0002.Цурко В. В., Громова М. А., Елисеева М. Е. Уратснижающая терапия подагры, акцент на фебуксостат (по материалам рекомендаций Европейской антиревматической лиги) // Трудный пациент. 2017. Т. 15, № 3, с. 24–26.Цурко В. В., Громова М. А., Елисеева М. Е. Уратснижающая терапия подагры, акцент на фебуксостат (по материалам рекомендаций Европейской антиревматической лиги) // Трудный пациент. 2017. Т. 15, № 3, с. 24–26.Цурко В. В., Громова М. А. Рационально обоснованный подход к лечению подагры с учетом дебюта, течения и сочетанной патологии по материалам рекомендации Европейской антиревматической лиги (EULAR, 2016) // Терапевт. Архив. 2017; 12 (вып. 2): 233–237.Цурко В. В., Громова М. А. Рационально обоснованный подход к лечению подагры с учетом дебюта, течения и сочетанной патологии по материалам рекомендации Европейской антиревматической лиги (EULAR, 2016) // Терапевт. Архив. 2017; 12 (вып. 2): 233–237.Akkineni R., Tapp S., Tosteson A. N. A. et al. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach // J. Rheumatol. 2014; 41 (4): 739–748. DOI: 10.3899/irheum.l21231; indexed in Pubmed: 24584921.Akkineni R., Tapp S., Tosteson A. N. A. et al. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach // J. Rheumatol. 2014; 41 (4): 739–748. DOI: 10.3899/irheum.l21231; indexed in Pubmed: 24584921.Seth R., Kydd A., Buchbinder R. et al. Allopurinol for chronic gout // Cochrane Database of Systematic Reviews. 2014, DOI: 10. 1002/14651858.cd006077.pub3; indexed in Pubmed: 25314636.Seth R., Kydd A., Buchbinder R. et al. Allopurinol for chronic gout // Cochrane Database of Systematic Reviews. 2014, DOI: 10. 1002/14651858.cd006077.pub3; indexed in Pubmed: 25314636.Becker M. A., Schumacher H. R., Wortmann R. L. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout // N. Engl. J. Med. 2005; 353 (23): 2450–2461. DOI: 10.1056/NEJMoa050373; indexed in Pubmed: 16339094.Becker M. A., Schumacher H. R., Wortmann R. L. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout // N. Engl. J. Med. 2005; 353 (23): 2450–2461. DOI: 10.1056/NEJMoa050373; indexed in Pubmed: 16339094.Цурко В. В., Громова М. А. Общие принципы и основные рекомендации по ведению и лечению пациентов с подагрой по материалам обновленных европейских рекомендаций // Consilium medicum. 2017; 19 (12): 20–24.Цурко В. В., Громова М. А. Общие принципы и основные рекомендации по ведению и лечению пациентов с подагрой по материалам обновленных европейских рекомендаций // Consilium medicum. 2017; 19 (12): 20–24.

The authors declare that there are no conflicts of interest present.